All. remember with anything new on the market, it never goes up every single week. There will be some down weeks even for a successful launch
Hope you have a good lawyer..they are coming for you and your identity here must be disclosed by Yahoo if served with a subpoena. Stating false information with intent to damage is an actionable.
But, you all can just watch and learn. Watch what happens to EpiFix sales for the balance of the year vs Grafix (any insurance coverage from MACs yet cause you know, you cant sell it if it isn't covered. Oh, I didn't think you had any of the 9 yet unlike EpiFix which has 9 of 9). By the end of the year Epifix will be firmly entrenched. of course, Epifix is not even where MDXG's future lies in any event.
Our reimbursement successes are attributed to the data we have collected in our peer-reviewed published clinical trials," stated Petit. "We have four different publications in Level One Journals on EpiFix®, our wound care allograft. We also have several other supporting scientific and clinical publications. Shortly, we will announce the publication of a 90-patient study on venous leg ulcers ("VLUs"). This is a multi-center, randomized, controlled trial involving seven centers. This should clear any questions on the effectiveness of EpiFix® on the larger VLU wounds. Shortly after this publication, we expect to announce another publication of a study of 60 patients with diabetic foot ulcers. This will bring our total study population to well over 200 patients.
And from the last conf call
And I will remind you of something I have also said before, our best sales through was simply the usage of EpiFix by just not any wound care physician. Scientists or researchers can argue all day long about which clinical study is better than some other study, but what’s non-debatable as a result of the use of a product in the hands of the typical wound care doctor in a widely diverse patient population. Our best sales through is to have a physician use an evaluation sample of EpiFix on a patient of theirs who had a chronic wound that he or she has not been able to close for months. And then we will come back to that position one or two weeks after that initial application, response when we see the doctor again is almost always the same.
What’s in that graft? The wound that is installed for months has either healed or significantly reduced the size. So personally, I don’t care if it’s better as a clinical study of 20, 50 or 500 people, none of them have shown the clinical performance of EpiFix noted most of them have the very simple logistics to the use of MiMedx. They can’t compete clinically or cost effectively so they try to focus and divert attention to something else.
Ozark, as an attorney allow me to explain to you how the doctor will respond to that question. "Because sir, the fact that one product has live cells and one has dead cells isn't relevant to my decision which product to use. My decision was based on clinical studies that showed EpiFix is more effective than Grafix. What is in the product doesn't concern me, only the results."
News on the very surprising injunction granted on one of their products..on Yahoo if you look. Just read a note that it is a blow to their pipeline. I know just the "fix" for them..Amniofix and Epifix
Saw this today and applies perfectly in this case. "never argue with an idiot. They will only bring you down to their level and beat you with experience."
It all started with pharmas being pressured in DC about lowering drug prices, then the general rotation out of stocks perceives as having lofty valuations. Stocks with ultra high PEs with the biggest runnups hardest hits. Bios and pharmas with no revenue easy targets for sell offs as they trade on future prospects since many have no revenue yet
Be afraid. be very afraid. Just like when you try to panic MDXG shareholders when it is down on light volume.
The CFO made a trip to the bank this week to deposit $15 million. Stock is tanking today. I don't understand. How can that be with all that cash and more on the way? I mean Apple has like $50 billion in cash and awarded a PE of 12. Wait, you think the market is concerned about how OSIR is going to compete with EpiFix when EpiFix is approved for reimbursement from 9 of the 9 MACs and Grafix is approved by zero of the 9 Macs? Silly me.